Rhabdoid Tumors and the Role of Chromatin Remodeling in Cancer

Brain Pathology

Volumn 23, Issue 2, 2013, Pages 200-205

  Lee, Ryan S ^a,b,c   Roberts, Charles W M ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

AT RT; cancer genomics; epigenetics; rhabdoid; SMARCB1; SWI SNF

Indexed keywords

AGE DISTRIBUTION; BLADDER CARCINOMA; CANCER PROGNOSIS; CANCER SUSCEPTIBILITY; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOME DELETION 22Q11; CHROMOSOME DELETION 22Q11.2; CLEAR CELL CARCINOMA; COLORECTAL CARCINOMA; CONFERENCE PAPER; DISEASE ASSOCIATION; DNA REPAIR; ENDOMETRIOID CARCINOMA; GENE INACTIVATION; GENE MUTATION; GENETIC ASSOCIATION; OVARY CARCINOMA; RHABDOID TUMOR; STOMACH CANCER; BRAIN TUMOR; CELL TRANSFORMATION; GENETICS; HUMAN; MUTATION; PATHOLOGY; REVIEW;

DNA BINDING PROTEIN; NONHISTONE PROTEIN; SMARCB1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

BRAIN NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA-BINDING PROTEINS; HUMANS; MUTATION; RHABDOID TUMOR; TRANSCRIPTION FACTORS;

EID: 84874495303     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/bpa.12021     Document Type: Conference Paper

References (87)

1. Betz BL, Strobeck MW, Reisman DN, Knudsen ES, Weissman BE, (2002) Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16ink4a and activation of RB. Oncogene 21: 5193-5203.
2. Biankin AV, Waddell N, Kassahn KS, Gingras M-C, Muthuswamy LB, Johns AL, et al (2012) Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491: 399-405.
3. Biegel JA, Kalpana G, Knudsen ES, Packer RJ, Roberts CWM, Thiele CJ, et al (2002) The role of INI1 and the SWI/SNF complex in the development of rhabdoid tumors: meeting summary from the workshop on childhood atypical teratoid/rhabdoid tumors. Cancer Res 62: 323-328.
4. Biegel JA, Rorke LB, Packer RJ, Emanuel BS, (1990) Monosomy 22 in rhabdoid or atypical tumors of the brain. J Neurosurg 73: 710-714.
5. Biegel JA, Tan L, Zhang F, Wainwright L, Russo P, Rorke LB, (2002) Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors. Clin Cancer Res 8: 3461-3467.
6. Biegel JA, Zhou JY, Rorke LB, Stenstrom C, Wainwright LM, Fogelgren B, (1999) Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 59: 74-79.
7. Bozic I, Antal T, Ohtsuki H, Carter H, Kim D, Chen S, et al (2010) Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci USA 107: 18545-18550.
8. Burger PC, Yu IT, Tihan T, Friedman HS, Strother DR, Kepner JL, et al (1998) Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study. Am J Surg Pathol 22: 1083-1092.
9. Cairns BR, Kim YJ, Sayre MH, Laurent BC, Kornberg RD, (1994) A multisubunit complex containing the SWI1/ADR6, SWI2/SNF2, SWI3, SNF5, and SNF6 gene products isolated from yeast. Proc Natl Acad Sci USA 91: 1950-1954.
10. Cancer Genome Atlas Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330-337.
11. Caramel J, Medjkane S, Quignon F, Delattre O, (2008) The requirement for SNF5/INI1 in adipocyte differentiation highlights new features of malignant rhabdoid tumors. Oncogene 27: 2035-2044.
12. Caramel J, Quignon F, Delattre O, (2008) RhoA-dependent regulation of cell migration by the tumor suppressor hSNF5/INI1. Cancer Res 68: 6154-6161.
13. Chai J, Charboneau AL, Betz BL, Weissman BE, (2005) Loss of the hSNF5 gene concomitantly inactivates p21CIP/WAF1 and p16INK4a activity associated with replicative senescence in A204 rhabdoid tumor cells. Cancer Res 65: 10192-10198.
14. Chi SN, Zimmerman MA, Yao X, Cohen KJ, Burger P, Biegel JA, et al (2009) Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol 27: 385-389.
15. Cornen S, Adelaide J, Bertucci F, Finetti P, Guille A, Birnbaum DJ, et al (2012) Mutations and deletions of ARID1A in breast tumors. Oncogene 31: 4255-4256.
16. Côté J, Quinn J, Workman JL, Peterson CL, (1994) Stimulation of GAL4 derivative binding to nucleosomal DNA by the yeast SWI/SNF complex. Science 265: 53-60.
17. Drost J, Mantovani F, Tocco F, Elkon R, Comel A, Holstege H, et al (2010) BRD7 is a candidate tumour suppressor gene required for p53 function. Nat Cell Biol 12: 380-389.
18. Duns G, Hofstra RMW, Sietzema JG, Hollema H, van, Duivenbode I, Kuik A, et al (2012) Targeted exome sequencing in clear cell renal cell carcinoma tumors suggests aberrant chromatin regulation as a crucial step in ccRCC development. Hum Mutat 33: 1059-1062.
19. Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, et al (2012) Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 44: 760-764.
20. Gadd S, Sredni ST, Huang C-C, Perlman EJ,; Group RTCOTCO (2010) Rhabdoid tumor: gene expression clues to pathogenesis and potential therapeutic targets. Lab Invest 90: 724-738.
21. Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao S, et al (2011) Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet 43: 875-878.
22. Guidi CJ, Sands AT, Zambrowicz BP, Turner TK, Demers DA, Webster W, et al (2001) Disruption of Ini1 leads to peri-implantation lethality and tumorigenesis in mice. Mol Cell Biol 21: 3598-3603.
23. Guo G, Gui Y, Gao S, Tang A, Hu X, Huang Y, et al (2012) Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nature Genetics 44: 17-19.
24. Hasselblatt M, Gesk S, Oyen F, Rossi S, Viscardi E, Giangaspero F, et al (2011) Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid/rhabdoid tumor showing retained SMARCB1 (INI1) expression. Am J Surg Pathol 35: 933-935.
25. Hasselblatt M, Isken S, Linge A, Eikmeier K, Jeibmann A, Oyen F, et al (2012) High-resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors. Genes Chromosomes Cancer 52: 185-190.
26. Ho L, Jothi R, Ronan JL, Cui K, Zhao K, Crabtree GR, (2009) An embryonic stem cell chromatin remodeling complex, esBAF, is an essential component of the core pluripotency transcriptional network. Proc Natl Acad Sci USA 106: 5187-5191.
27. Ho L, Ronan JL, Wu J, Staahl BT, Chen L, Kuo A, et al (2009) An embryonic stem cell chromatin remodeling complex, esBAF, is essential for embryonic stem cell self-renewal and pluripotency. Proc Natl Acad Sci USA 106: 5181-5186.
28. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat J-P, et al (2012) A landscape of driver mutations in melanoma. Cell 150: 251-263.
29. Huang J, Deng Q, Wang Q, Li K-Y, Dai J-H, Li N, et al (2012) Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet 44: 1117-1121.
30. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, et al (2012) Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150: 1107-1120.
31. Jackson EM, Sievert AJ, Gai X, Hakonarson H, Judkins AR, Tooke L, et al (2009) Genomic analysis using high-density single nucleotide polymorphism-based oligonucleotide arrays and multiplex ligation-dependent probe amplification provides a comprehensive analysis of INI1/SMARCB1 in malignant rhabdoid tumors. Clin Cancer Res 15: 1923-1930.
32. Jagani Z, Mora-Blanco EL, Sansam CG, McKenna ES, Wilson B, Chen D, et al (2010) Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway. Nat Med 16: 1429-1433.
33. Jones DTW, Jäger N, Kool M, Zichner T, Hutter B, Sultan M, et al (2012) Dissecting the genomic complexity underlying medulloblastoma. Nature 488: 100-105.
34. Jones S, Li M, Parsons DW, Zhang X, Wesseling J, Kristel P, et al (2012) Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat 33: 100-103.
35. Jones S, Wang T-L, Shih I-M, Mao T-L, Nakayama K, Roden R, et al (2010) Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330: 228-231.
36. Kaeser MD, Aslanian A, Dong M-Q, Yates JR, Emerson BM, (2008) BRD7, a novel PBAF-specific SWI/SNF subunit, is required for target gene activation and repression in embryonic stem cells. J Biol Chem 283: 32254-32263.
37. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, et al (1997) Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91: 649-659.
38. Kia SK, Gorski MM, Giannakopoulos S, Verrijzer CP, (2008) SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus. Mol Cell Biol 28: 3457-3464.
39. Kieran MW, Roberts CWM, Chi SN, Ligon KL, Rich BE, Macconaill LE, et al (2012) Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors. Pediatr Blood Cancer 59: 1155-1157.
40. Klochendler-Yeivin A, Fiette L, Barra J, Muchardt C, Babinet C, Yaniv M, (2000) The murine SNF5/INI1 chromatin remodeling factor is essential for embryonic development and tumor suppression. EMBO Rep 1: 500-506.
41. Klochendler-Yeivin A, Picarsky E, Yaniv M, (2006) Increased DNA damage sensitivity and apoptosis in cells lacking the Snf5/Ini1 subunit of the SWI/SNF chromatin remodeling complex. Mol Cell Biol 26: 2661-2674.
42. Lee RS, Stewart C, Carter SL, Ambrogio L, Cibulskis K, Sougnez C, et al (2012) A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest 122: 2983-2988.
43. Li M, Zhao H, Zhang X, Wood LD, Anders RA, Choti MA, et al (2011) Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet 43: 828-829.
44. Liu J, Lee W, Jiang Z, Chen Z, Jhunjhunwala S, Haverty PM, et al (2012) Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. Genome Res 22: 2315-2327.
45. Mamo A, Cavallone L, Tuzmen S, Chabot C, Ferrario C, Hassan S, et al (2012) An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. Oncogene 31: 2090-2100.
46. Manceau G, Letouzé E, Guichard C, Didelot A, Cazes A, Corté H, et al (2012) Recurrent inactivating mutations of ARID2 in non-small cell lung carcinoma. Int J Cancer [Epub ahead of print; doi: 10.1002/ijc.27900 ].
47. McKenna ES, Sansam CG, Cho Y-J, Greulich H, Evans JA, Thom CS, et al (2008) Loss of the epigenetic tumor suppressor SNF5 leads to cancer without genomic instability. Mol Cell Biol 28: 6223-6233.
48. McKenna ES, Tamayo P, Cho Y-J, Tillman EJ, Mora-Blanco EL, Sansam CG, et al (2012) Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors. Cell Cycle 11: 1956-1965.
49. Medina PP, Romero OA, Kohno T, Montuenga LM, Pio R, Yokota J, et al (2008) Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Hum Mutat 29: 617-622.
50. Northcott PA, Jones DTW, Kool M, Robinson GW, Gilbertson RJ, Cho Y-J, et al (2012) Medulloblastomics: the end of the beginning. Nat Rev Cancer 12: 818-834.
51. Olave I, Wang W, Xue Y, Kuo A, Crabtree GR, (2002) Identification of a polymorphic, neuron-specific chromatin remodeling complex. Genes Dev 16: 2509-2517.
52. Peña-Llopis S, Vega-Rubín-de-Celis S, Liao A, Leng N, Pavía-Jiménez A, Wang S, et al (2012) BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 44: 751-759.
53. Phelan ML, Sif S, Narlikar GJ, Kingston RE, (1999) Reconstitution of a core chromatin remodeling complex from SWI/SNF subunits. Mol Cell 3: 247-253.
54. Pugh TJ, Weeraratne SD, Archer TC, Pomeranz Krummel DA, Auclair D, Bochicchio J, et al (2012) Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 488: 106-110.
55. Reisman DN, Sciarrotta J, Wang W, Funkhouser WK, Weissman BE, (2003) Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. Cancer Res 63: 560-566.
56. Roberts CW, Galusha SA, McMenamin ME, Fletcher CD, Orkin SH, (2000) Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice. Proc Natl Acad Sci USA 97: 13796-13800.
57. Roberts CWM, Leroux MM, Fleming MD, Orkin SH, (2002) Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5. Cancer Cell 2: 415-425.
58. Rodriguez-Nieto S, Cañada A, Pros E, Pinto AI, Torres-Lanzas J, Lopez-Rios F, et al (2010) Massive parallel DNA pyrosequencing analysis of the tumor suppressor BRG1/SMARCA4 in lung primary tumors. Hum Mutat 32: E1999-E2017.
59. Rorke LB, Packer RJ, Biegel JA, (1996) Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity. J Neurosurg 85: 56-65.
60. Sausen M, Leary RJ, Jones SAN, Wu J, Reynolds CP, Liu X, et al (2012) Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet 45: 12-17.
61. Schneppenheim R, Frühwald MC, Gesk S, Hasselblatt M, Jeibmann A, Kordes U, et al (2010) Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. Am J Hum Genet 86: 279-284.
62. Seo J-S, Ju YS, Lee W-C, Shin J-Y, Lee JK, Bleazard T, et al (2012) The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 22: 2109-2119.
63. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA, (1996) Role of the INK4a locus in tumor suppression and cell mortality. Cell 85: 27-37.
64. Sévenet N, Lellouch-Tubiana A, Schofield D, Hoang-Xuan K, Gessler M, Birnbaum D, et al (1999) Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations. Hum Mol Genet 8: 2359-2368.
65. Sévenet N, Sheridan E, Amram D, Schneider P, Handgretinger R, Delattre O, (1999) Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers. Am J Hum Genet 65: 1342-1348.
66. Shain AH, Giacomini CP, Matsukuma K, Karikari CA, Bashyam MD, Hidalgo M, et al (2012) Convergent structural alterations define SWItch/sucrose nonfermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. Proc Natl Acad Sci USA 109: E252-E259.
67. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al (2012) The landscape of cancer genes and mutational processes in breast cancer. Nature 486: 400-404.
68. Taylor MD, Gokgoz N, Andrulis IL, Mainprize TG, Drake JM, Rutka JT, (2000) Familial posterior fossa brain tumors of infancy secondary to germline mutation of the hSNF5 gene. Am J Hum Genet 66: 1403-1406.
69. Tsikitis M, Zhang Z, Edelman W, Zagzag D, Kalpana GV, (2005) Genetic ablation of Cyclin D1 abrogates genesis of rhabdoid tumors resulting from Ini1 loss. Proc Natl Acad Sci USA 102: 12129-12134.
70. Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, et al (2011) Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469: 539-542.
71. Versteege I, Sévenet N, Lange J, Rousseau-Merck MF, Ambros P, Handgretinger R, et al (1998) Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394: 203-206.
72. Vries RGJ, Bezrookove V, Zuijderduijn LMP, Kia SK, Houweling A, Oruetxebarria I, et al (2005) Cancer-associated mutations in chromatin remodeler hSNF5 promote chromosomal instability by compromising the mitotic checkpoint. Genes Dev 19: 665-670.
73. Wang K, Kan J, Yuen ST, Shi ST, Chu KM, Law S, et al (2011) Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet 43: 1219-1223.
74. Wang L, Tsutsumi S, Kawaguchi T, Nagasaki K, Tatsuno K, Yamamoto S, et al (2012) Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency. Genome Res 22: 208-219.
75. Wang W, Côté J, Xue Y, Zhou S, Khavari PA, Biggar SR, et al (1996) Purification and biochemical heterogeneity of the mammalian SWI-SNF complex. EMBO J 15: 5370-5382.
76. Wang W, Xue Y, Zhou S, Kuo A, Cairns BR, Crabtree GR, (1996) Diversity and specialization of mammalian SWI/SNF complexes. Genes Dev 10: 2117-2130.
77. Wang X, Werneck MBF, Wilson BG, Kim H-J, Kluk MJ, Thom CS, et al (2011) TCR-dependent transformation of mature memory phenotype T cells in mice. J Clin Invest 121: 3834-3845.
78. Weeks DA, Beckwith JB, Mierau GW, Luckey DW, (1989) Rhabdoid tumor of kidney. A report of 111 cases from the National Wilms' Tumor Study Pathology Center. Am J Surg Pathol 13: 439-458.
79. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, et al (2012) The origin and evolution of mutations in acute myeloid leukemia. Cell 150: 264-278.
80. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, et al (2010) ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363: 1532-1543.
81. Williams BO, Remington L, Albert DM, Mukai S, Bronson RT, Jacks T, (1994) Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet 7: 480-484.
82. Wilson BG, Roberts CWM, (2011) SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 11: 481-492.
83. Wilson BG, Wang X, Shen X, McKenna ES, Lemieux ME, Cho Y-J, et al (2010) Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell 18: 316-328.
84. Wu JN, Roberts CWM, (2012) ARID1A mutations in cancer: another epigenetic tumor suppressor? Cancer Discov 3: 35-43.
85. Xia W, Nagase S, Montia AG, Kalachikov SM, Keniry M, Su T, et al (2008) BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer. Cancer Res 68: 1667-1674.
86. Zang ZJ, Cutcutache I, Poon SL, Zhang SL, McPherson JR, Tao J, et al (2012) Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 44: 570-574.
87. Zhang J, Benavente CA, Mcevoy J, Flores-Otero J, Ding L, Chen X, et al (2012)) A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 481: 329-334.